Phase III long-term safety study of SJP-0135 in patients with primary open-angle glaucoma or ocular hypertension
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Mar 2018
At a glance
- Drugs SJP 0135 (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Senju Pharmaceutical
- 12 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2017 New trial record
- 10 Mar 2017 Status has been changed from not yet recruiting to recruiting.